Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2640 - Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: results from S-TRAC trial

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Tumour Site

Renal Cell Cancer

Presenters

Daniel George

Citation

Annals of Oncology (2018) 29 (suppl_8): viii303-viii331. 10.1093/annonc/mdy283

Authors

D.J. George1, A.J. Pantuck2, R. Figlin3, B. Escudier4, S. Halabi5, M. Casey6, X. Lin7, L. Serfass8, M.J. Lechuga Frean9, A. Ravaud10

Author affiliations

  • 1 Division Of Oncology, Duke University Medical Center, 27710 - Durham/US
  • 2 Department Of Urology, Ronald Reagan UCLA Medical Center, 90024 - Los Angeles/US
  • 3 Medicine - Hematology Oncology, Cedars-Sinai Medical Center, 90048 - Los Angeles/US
  • 4 Department Of Medical Oncology, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
  • 5 Biostatistics And Bioinformatics, Duke University, 27710 - Durham/US
  • 6 Department Of Oncology, Pfizer Inc, Collegeville/US
  • 7 Oncology, Pfizer Inc, La Jolla/US
  • 8 Medical, Pfizer - France, 75014 - Paris/FR
  • 9 Oncology, Pfizer S.r.L, 20152 - Milan/IT
  • 10 Department Of Medical Oncology, CHU Bordeaux Hopital St. André, 33000 - Bordeaux/FR
More

Resources

Abstract 2640

Background

S-TRAC, a prospective phase 3 randomized trial in pts with resected RCC at high risk for recurrence, demonstrated a statistically significant improvement in DFS with sunitinib (SU) vs placebo; HR 0.76; 95% CI: 0.59, 0.98; P = 0.03. We hypothesized that DFS is a surrogate for OS and evaluated the association of DFS events with OS.

Methods

DFS (by blinded independent review) was defined from randomization to first evidence of recurrence, second primary malignancy, or death, whichever occurred first. Pts were categorized as having DFS or censored ≤2 years vs DFS >2 years, and as having OS or censored ≤5 years vs OS > 5 years. The odds ratio (OR), positive predictive values (PPV) and negative PV (NPV) were reported. To determine if DFS can be a surrogate for OS, 2 conditions need to be tested: 1) DFS and OS are strongly correlated, and 2) the treatment effect on DFS is sufficiently correlated with the effect on OS. The validity of the surrogate is reflected by the strength of these correlations. The correlation between DFS and OS is tested at the pt level through copula models to estimate the correlation coefficient (Kendall τ). Trial level correlations have been explored considering region as the trial unit.

Results

Median follow-up for OS was approximately 6.5 years with 141 (23%) observed deaths. There were 257 (42%) DFS events. Of 261 pts with DFS or censored ≤2 years of enrollment, 97 were alive and in follow-up >5 years (37%). In 354 pts with DFS >2 years, 318 pts were alive >5 years (90%). The OR, PPV and NPV were 14.9, 0.9 and 0.63, respectively. Kendall’s τ ranged from 0.51 to 0.88 using the Hougaard, Clayton, and Plackett copula, suggesting a moderate correlation at the individual pt level. Similar results were observed with investigator assessed DFS. Analyses of trial level correlations also suggest a moderate correlation. Further analyses are being explored.

Conclusions

A moderate correlation between DFS and OS was observed in S-TRAC despite immature OS data. Additional analyses across completed trials are warranted to further assess the relationship between DFS and OS.

Clinical trial identification

NCT00375674.

Legal entity responsible for the study

Pfizer.

Funding

Pfizer.

Editorial Acknowledgement

Editorial support was provided by Vardit Dror, PhD, of Engage Scientific Solutions, and funded by Pfizer.

Disclosure

D.J. George: Honoraria and consulting: Sanofi, Exelixis, Bayer; Consulting: Merck, Sanofi; Grants: Genentech/Roche, Novartis, Astellas, Celldex, Acerta; Grants & consulting: Exelixis, Janssen, Pfizer, Innocrin Pharma, BMS. A.J. Pantuck: Consulting fees: Pfizer. R. Figlin: Research funding: Peloton, BMS, Argos Therapeutics, Exilexis, and Cerulean; Consulting fees: Novartis, Pfizer, Nektar, Peloton, Calithera, Acceleron. B. Escudier: Consulting fees: Bayer, Pfizer, Novartis; Honoraria: Bayer, Roche, Pfizer, Genentech, Novartis, Aveo. S. Halabi: Data and Safety Monitoring Board member: Eisai. M. Casey, X. Lin, L. Serfass, M.J. Lechuga Frean: Employee of and own stock in Pfizer. A. Ravaud: Advisory boards: Pfizer, Novartis, GSK, Roche, BMS; Institutional support grants: Pfizer, Novartis; Housing and transportation for meetings and speeches: Pfizer, Novartis, BMS.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.